



Media Release
Zurich, June 26, 2026

Xlife Sciences Annual General Meeting approves all agenda items by a large majority and supports further expansion

Zurich, June 26, 2026: Today's Annual General Meeting of Xlife Sciences AG (SIX: XLS) approved all proposals of the Board of Directors. In total, 3'134'367 voting shares, corresponding to 54.3% of the total share capital, were represented.

David L. Deck, Chairman of the Board of Directors of Xlife Sciences AG, stated: «*The past year has shown that our strategy is working: we have further developed and consolidated our portfolio in a targeted manner and, with the listing of our portfolio company VERAXA as well as the planned Landsteiner platform, have laid strong foundations for the next phase of growth.*»

In addition to the approval of the agenda items, the importance of the participation in the Landsteiner Scientific platform was emphasized. This platform will serve as a key building block for the identification and development of novel therapeutic approaches as well as for global market access for Xlife Sciences' portfolio companies. By closely integrating academic research and entrepreneurial execution, the Landsteiner model will sustainably enhance access to innovative projects and form a central foundation for Xlife Sciences' future pipeline.

Furthermore, an outlook on upcoming capital market activities was presented, the new valuation report was explained, and progress across the broader portfolio was outlined.

Financial calendar
Half-Year Report 2026

24 September 2026

Contact

Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (SIX:XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.